^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    STAMP inhibitor

    Related drugs:
    3d
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)
    7d
    Asciminib real world study (ChiCTR2600116168)
    P4, N=200, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New P4 trial
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Scemblix (asciminib)
    9d
    ASC4CN: Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Scemblix (asciminib)
    17d
    Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    19d
    Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia. (PubMed, Eur J Clin Pharmacol)
    Overall, our findings showed that an adjustment of the initial asciminib dose may be needed based on genotyping information for the NR1I2 -25385C > T polymorphism and the body weight of the patient; however, further prospective studies are necessary.
    PK/PD data • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • NR1I2 (Nuclear Receptor Subfamily 1 Group I Member 2)
    |
    Scemblix (asciminib)
    29d
    Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=55, Enrolling by invitation, SWOG Cancer Research Network | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)
    1m
    Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia. (PubMed, Expert Rev Hematol)
    Particular attention is paid to how STAMP inhibition differs from ATP-competitive TKIs in terms of selectivity, toxicity profile, and resistance patterns, and how asciminib can be positioned relative to ponatinib in later-line settings.Asciminib has established itself as an effective and generally well-tolerated option for patients with TKI-resistant or -intolerant CML and is poised to expand into earlier lines of therapy. Its ability to induce rapid and deep molecular responses with reduced off-target toxicity may have important implications for long-term disease control and future treatment-free remission (TFR) strategies. Ongoing studies will clarify its optimal sequencing, combination potential, and role in facilitating durable TFR.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    1m
    DANTE: A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (clinicaltrials.gov)
    P2, N=124, Completed, Novartis Pharmaceuticals | Trial completion date: Jul 2026 --> Oct 2025 | Trial primary completion date: Jul 2026 --> Oct 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • TFRC
    |
    Tasigna (nilotinib) • Scemblix (asciminib)
    1m
    Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia. (PubMed, Front Cell Dev Biol)
    SiRNA-mediated FN1 knockdown reduced the cell's susceptibility to all generations of TKIs employed in treatment of CML, including asciminib...Clinically, deregulation of FN1 was also observed in peripheral blood cells derived from CML patients. Our data indicate that FN1 may serve as a potential therapeutic target to address TKI resistance or as a suitable biomarker for the treatment.
    Journal
    |
    FN1 (Fibronectin 1) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
    |
    ABL1 T315I
    |
    imatinib • Scemblix (asciminib)
    2ms
    RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Scemblix (asciminib)
    2ms
    ASSURE-3: Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (clinicaltrials.gov)
    P=N/A, N=201, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    Scemblix (asciminib)
    2ms
    ASCENdANT: Asciminib in HER2+ Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    Herceptin (trastuzumab) • Scemblix (asciminib)